European Countries Should Join Forces To Lower Prices of Zolgensma & Kaftrio
The Dutch HTA institute is calling for hefty discounts of 50% and 75% for Novartis’s gene therapy and Vertex’s cystic fibrosis product.
You may also be interested in...
BeNeLuxA, the cross-country medicines access initiative, says it is now the “gold standard” for voluntary collaboration in Europe after a ground-breaking deal was reached with Novartis.
ZIN, the Dutch health technology appraisal institute, has slammed the pricing of another rare disease treatment.
The Netherlands calls for multi-country price negotiations for gene therapy Zynteglo.